New Combination Treatment Approved for Non-Small Cell Lung Cancer
December 7, 2018
The Food and Drug Administration (FDA) approved atezolizumab (TECENTRIQ®), an immunotherapy drug, in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic non-squamous, non-small cell lung cancer (NSq NSCLC) with no EGFR or ALK genomic tumor aberrations.This is the first four drug combination treatment approved for lung cancer.Click here to learn more.
Lung cancer questions? Contact our free HelpLine at support@go2.org or 1-800-298-2436.